CJON:对肝癌及转移性肝癌合理使用HAIP

2015-06-10 MedSci MedSci原创

背景:化疗时使用肝动脉输注泵(HAIP)开始于20世纪60年代,用于治疗不易局部治疗或手术切除的转移性肝部肿瘤。由于采用HAIP会存在很多并发症并且不能有效提高生存率,因此之后很少使用HAIP。但现如今各种不同形式的HAIP有望重新登上历史舞台并且发挥作用,但很少有资料提及在护理活动中如何对患者进行健康宣教及使用指导。目标:该研究的目的在于:对有HAIP的患者,将HAIP的用法、使用步骤和护理指导

背景:化疗时使用肝动脉输注泵(HAIP)开始于20世纪60年代,用于治疗不易局部治疗或手术切除的转移性肝部肿瘤。由于采用HAIP会存在很多并发症并且不能有效提高生存率,因此之后很少使用HAIP。但现如今各种不同形式的HAIP有望重新登上历史舞台并且发挥作用,但很少有资料提及在护理活动中如何对患者进行健康宣教及使用指导。

目标:该研究的目的在于:对有HAIP的患者,将HAIP的用法、使用步骤和护理指导等健康宣教进行告知。

方式:该研究为一篇系统综述,取材来自于各种出版刊物中提及到HAIP的各种文献资料。

结果:研究人员初步选择了511篇相关文章和摘要。在排除内容相近或一致的复制品和无关文章之后,我们一共选取了65篇文章,并进行了阅读和分析。之后又排除了不符合取材标准的20篇文章。

补充肝癌及转移性肝癌化疗前后心理护理要点:

心理护理是术前护理的重要环节。肝癌患者大多数情绪不稳定,处于焦虑、恐惧心理状态,缺乏治疗信心,或者根本不知晓自己的病情。在护理工作中要及时了解患者的心理状态,耐心倾听患者的主诉,了解其对手术的顾虑,有针对性地进行疏导。向患者介绍治疗目的、步骤、效果、不良反应和术中配合要点,介绍介入治疗手术的优点,如创伤小、安全、恢复快、效果好等。把成功的病例告知病人,使患者对治疗有全面了解,在思想上、精神上做好充分准备,以良好的心态接受治疗。对于不了解自己病情的患者,医务人员要做好保密工作。

由于介入治疗后出现的副反应如恶心、呕吐、乏力、疼痛、发热等,可使患者情绪出现波动,因此针对患者的心理特点,做好沟通工作,消除恐惧心理。护理人员应主动听取病人的主诉,以点头,微笑等体态语言表示理解,耐心解答病人的问题,帮助病人度过术后不适阶段,树立战胜疾病的信念。

原始出处:

Lisa Parks, Meghan Routt.Hepatic Artery Infusion Pump in the Treatment of Liver Metastases.CJON 2015, 19(3), 316-320.DOI: 10.1188/15.CJON.316-320

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771674, encodeId=377c1e71674cf, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Fri Apr 08 22:55:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37662, encodeId=535e3e66280, content=可惜化疗不敏感呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af5b1653618, createdName=Charles Chow, createdTime=Sat Oct 03 14:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29555, encodeId=3a7729555e6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27942, encodeId=ee1a2e9427e, content=优化治疗的模式, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19311619842, createdName=xcjick, createdTime=Wed Jun 17 12:13:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386162, encodeId=76bf138616215, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 12 12:55:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27256, encodeId=96792e25673, content=目前我们使用减少了,有点麻烦,耗时, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Fri Jun 12 09:53:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771674, encodeId=377c1e71674cf, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Fri Apr 08 22:55:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37662, encodeId=535e3e66280, content=可惜化疗不敏感呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af5b1653618, createdName=Charles Chow, createdTime=Sat Oct 03 14:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29555, encodeId=3a7729555e6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27942, encodeId=ee1a2e9427e, content=优化治疗的模式, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19311619842, createdName=xcjick, createdTime=Wed Jun 17 12:13:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386162, encodeId=76bf138616215, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 12 12:55:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27256, encodeId=96792e25673, content=目前我们使用减少了,有点麻烦,耗时, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Fri Jun 12 09:53:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-10-03 Charles Chow

    可惜化疗不敏感呢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1771674, encodeId=377c1e71674cf, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Fri Apr 08 22:55:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37662, encodeId=535e3e66280, content=可惜化疗不敏感呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af5b1653618, createdName=Charles Chow, createdTime=Sat Oct 03 14:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29555, encodeId=3a7729555e6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27942, encodeId=ee1a2e9427e, content=优化治疗的模式, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19311619842, createdName=xcjick, createdTime=Wed Jun 17 12:13:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386162, encodeId=76bf138616215, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 12 12:55:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27256, encodeId=96792e25673, content=目前我们使用减少了,有点麻烦,耗时, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Fri Jun 12 09:53:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-26 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1771674, encodeId=377c1e71674cf, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Fri Apr 08 22:55:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37662, encodeId=535e3e66280, content=可惜化疗不敏感呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af5b1653618, createdName=Charles Chow, createdTime=Sat Oct 03 14:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29555, encodeId=3a7729555e6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27942, encodeId=ee1a2e9427e, content=优化治疗的模式, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19311619842, createdName=xcjick, createdTime=Wed Jun 17 12:13:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386162, encodeId=76bf138616215, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 12 12:55:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27256, encodeId=96792e25673, content=目前我们使用减少了,有点麻烦,耗时, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Fri Jun 12 09:53:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-17 xcjick

    优化治疗的模式

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1771674, encodeId=377c1e71674cf, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Fri Apr 08 22:55:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37662, encodeId=535e3e66280, content=可惜化疗不敏感呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af5b1653618, createdName=Charles Chow, createdTime=Sat Oct 03 14:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29555, encodeId=3a7729555e6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27942, encodeId=ee1a2e9427e, content=优化治疗的模式, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19311619842, createdName=xcjick, createdTime=Wed Jun 17 12:13:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386162, encodeId=76bf138616215, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 12 12:55:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27256, encodeId=96792e25673, content=目前我们使用减少了,有点麻烦,耗时, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Fri Jun 12 09:53:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1771674, encodeId=377c1e71674cf, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Fri Apr 08 22:55:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37662, encodeId=535e3e66280, content=可惜化疗不敏感呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af5b1653618, createdName=Charles Chow, createdTime=Sat Oct 03 14:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29555, encodeId=3a7729555e6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27942, encodeId=ee1a2e9427e, content=优化治疗的模式, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19311619842, createdName=xcjick, createdTime=Wed Jun 17 12:13:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386162, encodeId=76bf138616215, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 12 12:55:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27256, encodeId=96792e25673, content=目前我们使用减少了,有点麻烦,耗时, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Fri Jun 12 09:53:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-12 huangwukui

    目前我们使用减少了,有点麻烦,耗时

    0

相关资讯

非酒精性脂肪肝生物标志物已经被识别

在欧盟国家中有40%的个体都遭受着非酒精性脂肪性肝炎的痛苦,在当前富裕社会下这种疾病的流行率越来越高,其也是个体糖尿病和体重过度增加的直接结果,当前研究者并不可能预测这种疾病的未来发展情况,而其直接的结果似乎只能是肝硬化和肝癌,此外其也会增加个体患心脏病发作及肾脏损伤的风险,未来研究者或将利用不同生物标志物的风险评分来对该疾病进行预测。 来自维也纳医科大学的研究者表示,我们开发的这种风险

Cell Stem Cell:中科院科学家在肝癌干细胞自我更新机制研究中取得新进展

2015年4月2日,中科院生物物理所范祖森课题组和陈润生院士课题组在国际权威期刊Cell Stem Cell杂志发表了题为“The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling”的研究论文。文章报告了关于长

EASL 2015:外显子组测序有助于肝癌个体化治疗

第50届欧洲肝脏研究学会(EASL)年会上公布的数据显示,肝脏肿瘤外显子组测序可有效判断环境暴露和变异特征之间的关系,这可能有助于确定将来肝癌患者的治疗。(摘要号:G05) 法国巴黎勒内?迪卡尔大学医学教授,INSERM(全国保健和医学研究院)院长,巴黎实体肿瘤功能基因组学的Jessica Zucman-Rossi博士和他的同事对欧洲患者中的肝硬化(F4,n = 118),纤维化(F2和F3

Nat Commun:科学家揭示肝癌干细胞自我更新的分子机制

肝癌是我国最严重的肿瘤之一,也是世界上五大常见癌症之一,因此,揭示肝癌发病机制具有迫切性和重要临床意义。近年来,肿瘤干细胞学说受到了的高度关注和认可,肿瘤干细胞具有自我更新和可塑性潜能,在启动肿瘤形成和生长中起着决定性作用,现有的治疗措施尚无法针对肿瘤干细胞发挥作用,这可能是导致肝癌复发和耐药的主要原因。肿瘤干细胞具有极强的耐药性和转移特征,因此,针对肿瘤干细胞的靶向治疗有可能是解决肿瘤转移和复发

Cell reports:YAP抑制晚期肝癌细胞分化治疗肝癌新策略

                                                        &nb

Nat Commun:全基因组测序揭示肝炎与肝癌新联系

最近,日本理化学所(RIKEN)的科学家们,利用全基因组测序首次证实,慢性肝炎和炎症可能对肝脏肿瘤中发现的基因突变产生深远的影响,从而为更好理解慢性肝炎导致癌症的机制,铺平了道路。相关研究结果发表在最近的《自然通讯》(Nature Communications)。 原发性肝癌是全世界癌症死亡的第三大原因,最近的研究表明,特别是在亚洲,感染乙型或丙型肝炎病毒,往往与这类癌症有关。肝癌从细